Table 2 Summary of treatment exposure
Treatment exposure | US commercial cetuximab Arm A (N = 77) | BI-manufactured cetuximab Arm B (N = 71) |
|---|---|---|
Median duration of treatment (25th percentile, 75th percentile), weeks | ||
Cetuximab | 12.4 (6.0, 18.0) | 13.6 (6.0, 20.0) |
Cisplatin | 6.9 (3.0, 14.0) | 9.0 (3.0, 18.0) |
Carboplatin | 12.6 (6.1, 18.0) | 15.0 (7.0, 20.0) |
5-FU | 13.0 (6.0, 17.9) | 13.0 (6.3, 20.0) |
Relative dose intensity, % | ||
Cetuximab | 87.5 | 87.1 |
Cisplatin | 86.8 | 87.9 |
Carboplatin | 94.3 | 88.4 |
5-FU | 84.1 | 82.9 |